Bluebird Bio Inc. (BLUE)

Trade BLUE now with
1/18/2023 6:46:21 AM Bluebird Bio Commences Underwritten Public Offering Of 20 Mln Shares Of Common Stock
1/6/2023 7:32:10 AM Bluebird Bio Sells Second Rare Pediatric Disease Priority Review Voucher For $95 Mln
1/3/2023 8:06:43 AM Bluebird Bio Appoints Joseph Vittiglio As Chief Business And Legal Officer
12/19/2022 7:34:00 AM Bluebird Bio: FDA Lifts Partial Clinical Hold For Company's Sickle Cell Disease Studies For Patients Under Age Of 18
12/10/2022 12:38:01 PM Bluebird Bio Presents New And Updated Data From Gene Therapy Programs In Beta-thalassemia And Sickle Cell Disease
11/30/2022 7:06:42 AM Bluebird Bio To Sell Rare Pediatric Disease Priority Review Voucher For $102 Mln
11/7/2022 7:08:24 AM Bluebird Bio Q3 Net Loss From Cont Opns Narrows To $76.5 Mln From $216.8 Mln Prior Year
9/19/2022 10:34:46 AM Bluebird Stock Slips 13%
9/12/2022 7:38:17 AM Bluebird Chief Strategy And Financial Officer Jason Cole Plans To Leave Company This Fall